Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein

Nature Biotechnology

Volumn 28, Issue 3, 2010, Pages 256-263

  Bauer, Peter O ^a   Goswami, Anand ^a   Wong, Hon Kit ^a   Okuno, Misako ^a   Kurosawa, Masaru ^a   Yamada, Mizuki ^a   Miyazaki, Haruko ^a   Matsumoto, Gen ^a   Kino, Yoshihiro ^a   Nagai, Yoshitaka ^b   Nukina, Nobuyuki ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR MOLECULE; BINDING MOTIF; BINDING PEPTIDE; CHAPERONE-MEDIATED AUTOPHAGY; CULTURED CELL; HEAT-SHOCK; HUNTINGTON'S DISEASE; MISFOLDED PROTEINS; MOUSE MODELS; MUTANT HUNTINGTIN; POLYGLUTAMINE; POLYGLUTAMINE (POLYQ); SELECTIVE DEGRADATION; SPECIFIC BINDING; THERAPEUTIC POTENTIALS;

DEGRADATION; MOLECULES; VIRUSES;

PROTEINS;

CHAPERONE; HEAT SHOCK COGNATE PROTEIN 70; HUNTINGTIN; PEPTIDE DERIVATIVE; POLYGLUTAMINE BINDING PEPTIDE 1; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CELL CULTURE; CONTROLLED STUDY; FEMALE; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MOTIF;

AMINO ACID MOTIFS; ANIMALS; AUTOPHAGY; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; HSC70 HEAT-SHOCK PROTEINS; HUMANS; HUNTINGTON DISEASE; MICE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGOPEPTIDES; PEPTIDES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RATS; RECOMBINANT FUSION PROTEINS;

EID: 77749319356     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1608     Document Type: Article

References (61)

1. Zoghbi, H.Y. & Orr, H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
2. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
3. Davies, S.W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (1997).
4. Perutz, M.F., Pope, B.J., Owen, D., Wanker, E.E. & Scherzinger, E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc. Natl. Acad. Sci. USA 99, 5596-5600 (2002).
5. Tanaka, M. et al. Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fbrillization. J. Biol. Chem. 278, 34717-34724 (2003).
6. Dunah, A.W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243 (2002).
7. Nucifora, F.C. Jr. et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428 (2001).
8. Yamanaka, T. et al. Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J. 27, 827-839 (2008).
9. Bauer, P.O. & Nukina, N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 110, 1737-1765 (2009).
10. Yamamoto, A., Lucas, J.J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66 (2000).
11. Wang, Y.L. et al. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res. 53, 241-249 (2005).
12. DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral defcits. Proc. Natl. Acad. Sci. USA. 104, 17204-17209 (2007).
13. Harper, S.Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA. 102, 5820-5825 (2005).
14. Rodriguez-Lebron, E., Denovan-Wright, E.M., Nash, K., Lewin, A.S. & Mandel, R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12, 618-633 (2005).
15. Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fy and mouse models of Huntington disease. Nat. Genet. 36, 585-595 (2004).
16. Sarkar, S. et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3, 331-338 (2007).
17. Wong, H.K. et al. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum. Mol. Genet. 17, 3223-3235 (2008).
18. Bauer, P.O. et al. Inhibition of rho kinases enhances the degradation of mutant huntingtin. J. Biol. Chem. 284, 13153-13164 (2009).
19. Mizushima, N., Ohsumi, Y. & Yoshimori, T. Autophagosome formation in mammalian cells. Cell. Struct. Funct. 27, 421-429 (2002).
20. Cuervo, A.M. & Dice, J.F. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 273, 501-503 (1996).
21. Agarraberes, F.A. & Dice, J.F. A molecular chaperone complex at the lysosomal membrane is required for protein translocation. J. Cell Sci. 114, 2491-2499 (2001).
22. Nagai, Y. et al. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identifed by phage display screening. J. Biol. Chem. 275, 10437-10442 (2000).
23. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T. & Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295 (2004).
24. Cuervo, A.M., Mann, L., Bonten, E.J., d'Azzo, A. & Dice, J.F Cathepsin A regulates chaperone-mediated autophagy through cleavage of the lysosomal receptor. EMBO J. 22, 47-59 (2003).
25. Nagai, Y. et al. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet. 12, 1253-1259 (2003).
26. Nagai, Y. et al. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14, 332-340 (2007).
27. Tsutsui, H., Karasawa, S., Shimizu, H., Nukina, N. & Miyawaki, A. Semi-rational engineering of a coral fuorescent protein into an effcient highlighter. EMBO Rep. 6, 233-238 (2005).
28. Rodriguez-Enriquez, S., Kim, I., Currin, R.T. & Lemasters, J.J. Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepatocytes. Autophagy 2, 39-46 (2006).
29. Weiss, A. et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J. Neurochem. 104, 846-858 (2008).
30. Kotliarova, S. et al. Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fuorescent aggregates. J. Neurochem. 93, 641-653 (2005).
31. Beal, M.F. & Ferrante, R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5, 373-384 (2004).
32. Li, J.Y., Popovic, N. & Brundin, P. The use of the R6 transgenic mouse models of Huntington's Disease in attempts to develop novel therapeutic strategies. NeuroRx 2, 447-464 (2005).
33. Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148-154 (2004).
34. Sanchez, I., Mahlke, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379 (2003).
35. Karpuj, M.V. et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. USA 96, 7388-7393 (1999).
36. Karpuj, M.V. et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143-149 (2002).
37. Dedeoglu, A. et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942-8950 (2002).
38. Ferrante, R.J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003).
39. Smith, K.M. et al. Dose ranging and effcacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762, 616-626 (2006).
40. Nguyen, T., Hamby, A. & Massa, S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102, 11840-11845 (2005).
41. Ona, V.O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267 (1999).
42. Jin, K. et al. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 102, 18189-18194 (2005).
43. Peng, Q. et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 210, 154-163 (2008).
44. Ferrante, R.J. et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 24, 10335-10342 (2004).
45. Ryu, H. et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. USA 103, 19176-19181 (2006).
46. Popiel, H.A., Nagai, Y., Fujikake, N. & Toda, T. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci. Lett. 449, 87-92 (2009).
47. Southwell, A.L., Ko, J. & Patterson, P.H. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 29, 13589-13602 (2009).
48. Harper, S.Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102, 5820-5825 (2005).
49. Rodriguez-Lebron, E., Denovan-Wright, E.M., Nash, K., Lewin, A.S. & Mandel, R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12, 618-633 (2005).
50. DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral defcits. Proc. Natl. Acad. Sci. USA 104, 17204-17209 (2007).
51. Huang, B. et al. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum. Gene Ther. 18, 303-311 (2007).
52. Zhang, Y., Engelman, J. & Friedlander, R.M. Allele-specifc silencing of mutant Huntington's disease gene. J. Neurochem. 108, 82-90 (2009).
53. Cho, S.R. et al. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J. Clin. Invest. 117, 2889-2902 (2007).
54. Southwell, A.L. et al. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J. Neurosci. 28, 9013-9020 (2008).
55. Emadi, S., Barkhordarian, H., Wang, M.S., Schulz, P. & Sierks, M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol. 368, 1132-1144 (2007).-
56. Lynch, S.M., Zhou, C. & Messer, A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 377, 136-147 (2008).
57. Wang, G.H. et al. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 10, 2435-2438 (1999).
58. Wang, G.H., Sawai, N., Kotliarova, S., Kanazawa, I. & Nukina, N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum. Mol. Genet. 9, 1795-1803 (2000).
59. Peters, M.F. & Ross, C.A. Preparation of human cDNas encoding expanded polyglutamine repeats. Neurosci. Lett. 275, 129-132 (1999).
60. Zemskov, E.A. et al. Pro-apoptotic protein kinase C delta is associated with intranuclear inclusions in a transgenic model of Huntington's disease. J. Neurochem. 87, 395-406 (2003).
61. Madden, E.A., Wirt, J.B. & Storrie, B. Purifcation and characterization of lysosomes from Chinese hamster ovary cells. Arch. Biochem. Biophys. 257, 27-38 (1987).